These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26995488)

  • 41. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients.
    Hung TY; Kotecha RS; Blyth CC; Steed SK; Thornton RB; Ryan AL; Cole CH; Richmond PC
    Cancer; 2017 Nov; 123(21):4215-4223. PubMed ID: 28696530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy.
    Caporuscio S; Ieraci R; Valesini G; Teloni R; Mariotti S; Spinelli FR; Ferlito C; Salemi S; Picchianti Diamanti A; Meneguzzi G; Markovic M; Sgrulletti M; von Hunolstein C; Ralli L; Pinto A; Salerno G; Canzoni M; Sorgi ML; Laganà B; Di Rosa R; Nisini R; D'Amelio R
    Clin Immunol; 2018 Oct; 195():18-27. PubMed ID: 30036638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA).
    Nguyen M; Lindegaard H; Hendricks O; Friis-Møller N
    Scand J Rheumatol; 2017 Nov; 46(6):446-453. PubMed ID: 28145151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
    Park JK; Lee MA; Lee EY; Song YW; Choi Y; Winthrop KL; Lee EB
    Ann Rheum Dis; 2017 Sep; 76(9):1559-1565. PubMed ID: 28468794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine.
    Klein NP; Ensor K; Jouve S; Northington R; Moscariello M; McGovern PC
    Pediatr Infect Dis J; 2013 Sep; 32(9):990-7. PubMed ID: 24008739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment.
    Nived P; Saxne T; Geborek P; Mandl T; Skattum L; Kapetanovic MC
    BMC Rheumatol; 2018; 2():12. PubMed ID: 30886963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.
    Nagel J; Geborek P; Saxne T; Jönsson G; Englund M; Petersson IF; Nilsson JÅ; Kapetanovic MC
    Scand J Rheumatol; 2015; 44(4):271-9. PubMed ID: 25656734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
    Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis.
    Hesselstrand R; Nagel J; Saxne T; Geborek P; Skattum L; Kapetanovic MC
    Rheumatology (Oxford); 2018 Apr; 57(4):625-630. PubMed ID: 29325173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.
    Bryant KA; Frenck R; Gurtman A; Rubino J; Treanor J; Thompson A; Jones TR; Sundaraiyer V; Baxter LM; Gruber WC; Emini EA; Scott DA; Schmoele-Thoma B
    Vaccine; 2015 Oct; 33(43):5854-5860. PubMed ID: 26362099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
    Winthrop KL; Bingham CO; Komocsar WJ; Bradley J; Issa M; Klar R; Kartman CE
    Arthritis Res Ther; 2019 Apr; 21(1):102. PubMed ID: 30999933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
    Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
    PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
    Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
    Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
    O'Brien KL; Swift AJ; Winkelstein JA; Santosham M; Stover B; Luddy R; Gootenberg JE; Nold JT; Eskenazi A; Snader SJ; Lederman HM
    Pediatrics; 2000 Nov; 106(5):965-72. PubMed ID: 11061761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
    Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.